Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026

LONDON, May 31, 2016 /PRNewswire/ --

Opportunities for Leading Companies 

Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies - our new Study Reveals Trends, R&D Progress, and Predicted Revenues 

Our new report discusses issues and events affecting the Alzheimer's disease therapeutics and diagnostics market. Our new report provides qualitative analyses to answer these key questions:
• How is the Alzheimer's disease therapeutics and diagnostics market evolving?
• What is driving and restraining the Alzheimer's disease therapeutics and diagnostics market growth?
• Which type of diagnostics will be the main drivers of the overall market from 2016 to 2026?
• How will political and regulatory factors influence the regional markets and submarkets?
• Who are the leading Alzheimer's disease therapeutics and diagnostics companies, and what are their prospects over the forecast period?
• What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?

Forecasts from 2016-2026 and other analyses show you commercial prospects
Our new report provides quantitative analyses to answer these key questions:
• What are the market shares of the Alzheimer's therapeutics disease market and Alzheimer's diagnostics market in 2015?
• How will each of the drugs in the Alzheimer's therapeutics market grow over the forecast period and how much revenue will these drugs account for in 2026?
• What Alzheimer's disease drugs are in the development pipeline and what revenues will these drugs make when they come on the market?
• How will each of Alzheimer's disease diagnostics market grow over the forecast period and how much revenue will these submarkets account for in 2026?
• How will the market shares of the national markets change by 2026 and which geographical region will lead the market in 2026?

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. We provide original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Mr. Timothy Earle, Chief Operating Officer / Chief Business Officer, TauRx Pharmaceuticals Ltd
• Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
• The Alzheimer's Association Northern California and Northern Nevada

Many opportunities exist for diagnosis and treatment of Alzheimer's. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead

Discover sales predictions for the world market and submarkets
Along with revenue prediction of the overall world market, you see forecasts to 2026 for these two submarkets:
• Medicines for Alzheimer's disease
• Diagnostics for Alzheimer's (including biomarkers).

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for Alzheimer's disease drugs
How will leading drugs perform to 2026 at world level? Our study predicts individual revenues of three products:
• Namenda
• Aricept
• Exelon

And also three pipeline products:
• Solanezumab
• Gantenerumab
• MK-8931

What are the prospects in the leading regions and countries?
Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2015. The US remains the largest national market by value, accounting for 40% of global revenues.
In addition to analyses of the overall world market, you discover revenue forecasts for 12 leading national markets to 2026:
• US
• Japan
• Germany
• France
• UK
• Spain
• Italy
• China
• Brazil
• Russia
• India
• Rest of the World

Leading companies and potential for market growth
In 2015, the overall world market for Alzheimer's disease therapeutics and diagnostics was worth $7.0bn, having experienced a plateau in revenue over recent years. Within this forecast period, revenue growth will increase in the second half of the forecast period due to the expected launch of new drugs. There are around 9 drugs in phase III of clinical development.
Our work shows you what organisation hold greatest potential. See profiles of leading companies in this sector:
• Pfizer
• Eisai
• Actavis
• Lundbeck
• Daiichi Sankyo
• Novartis
• TauRx
• vTv Therapeutics

In general, a company profile gives you the following information:
• Revenue forecasts for Alzheimer's disease drugs from 2015 to 2026
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, collaborations, including alliances, partnerships and joint ventures.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What affects producers of those diagnostic tests and medicines?
Our report discusses issues and events affecting that industry and market from 2015, including these:
• Research and development (R&D) - drugs, diagnostic tests, and related technologies
• Disease prevalence - expanding patient populations
• Disease-modifying drugs and obstacles to cures
• Regulatory guidelines - changes and opportunities.

The study also discusses other aspects of diagnosing and treating Alzheimer's:
• Needs for Alzheimer's treatments
• Drugs and related technologies to transform the market
• Biomarkers and diagnostic imaging technologies, including structural, functional, and molecular imaging
• Diagnostic tests in development
• Deep brain stimulation (functional neuromodulation)
• Intellectual property (IP), licensing agreements and partnerships.

Our 200-page report provides 132 charts. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.
Benefit your work now through our updated study, gaining original industry and market analysis:
• Revenues for Alzheimer's disease therapeutics and diagnostics market to 2026 at world level, also for Alzheimer's drug submarket and Diagnostics submarket (Diagnostics Biomarkers and Others) and 3 medicines - assess outlooks for development, production, marketing and sales
• Forecasts to 2026 for 12 national markets in the Americas, Europe and Asia - investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies and new entrants - explore portfolios, technologies, results, strategies, R&D and outlooks for success
• Analysis and forecast for Alzheimer's pipeline drugs and diagnostics - uncover pipeline drugs, diagnostics, their forecast and recent development status
• Discussions of research and development - see progress in that industry, finding technological, clinical and commercial outlooks and opportunities
• Opinions from companies and other organisations - discover, through three interviews, views to help you stay ahead in knowledge
• Analysis of what stimulates and restrains that Alzheimer's disease therapeutics and diagnostics market - assess challenges and strengths, helping you compete and gain advantages.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100  Or click on https://www.visiongain.com/Report/1641/Alzheimer%E2%80%99s-Disease-Therapeutics-and-Diagnostics-Market-Forecast-2016-2026

Companies mentioned in this Report 

AbbVie

AC Immune

Acadia Pharmaceuticals

Accera

Actavis

Adamas Pharmceuticals

Affiris

Amarantus BioSciences

Amorphis

Archer Pharmaceuticals

Astex

AstraZeneca

Avanir Pharmaceuticals

Avineuro Pharmaceuticals

Baxter

Bayer

Bayer Schering Pharma

Biogen

bioMerieux

Ceregene

Chiesi Farmaceutici

Cognoptix

Cytos

Daiichi Sankyo

DiaGenic

Eisai

Elan

Eli Lilly

EnVivo Pharmaceuticals

Forest Laboratories

Forum Pharmaceuticals

Foundation Medical Partners

Functional Neuromodulation

GE Healthcare

General Electric

Genervon Biopharmaceuticals

Genesys Capital

GSK

Hisamitsu Pharmaceutical

Humanetics

IBA Molecular

J&J

Janssen Alzheimer Immunotherapy Research & Development

Janssen Pharmaceutical K. K

Kareus Therapeutics

LabCorp

Luminex

Lundbeck

Medtronic

Merck & Co

Merz

Meso Scale Diagnostics

Metabolic Solutions Development Company

MorphoSys

Nanotherapeutics

Navidea

NextGen Sciences

Novartis

Novo Nordisk

Ono Pharmaceutical

OPKO

Ortho Clinical Diagnostics

Otsuka Pharmaceutical

Oxford BioDynamics

Par Pharmaceuticals

Pfizer

Piramal Enterprises

Piramal Imaging

Proteome Sciences

ProteoTech

Proterra

QR Pharma

Quanterix

Raptor Pharmaceutical

Resverlogix

Roche

Roche Diagnostics

Saladax

Sangamo BioSciences

Sanofi

sGC Pharma

Shionogi

Shire

Siemens Medical Solutions USA

Somalogic

Sonexa Therapeutics

Sun Pharma

T3D Therapeutics

Takeda

Targacept

TauRx

Toyama Chemical

Transition Therapeutics

TransTech Pharma

United Biomedical

VIVUS

Wyeth

Alzheimer's Association International Conference (AAIC)

Alzheimer's Research UK

Assogenerici (Italy)

Cambridge University

Cleveland Clinic Lou Ruvo Center for Brain Health

Dementia UK

French Economic Committee

King's College London

Ministry of Health, Labout and Welfare (MHLW) (Japan)

National Health Services (Italy)

National Health Services (NHS) (UK)

National Institute of Clinical Excellence (NICE)

National Institute of Health (NIH)

The Alzheimer's Association

The Centers for Medicare and Medicaid Services (CMS)

The Central Drug Standard Control Organisation (CDSCO)

The Duke University

The European Commission

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)

The Food and Drug Administration FDA (US)

The Health and Social Care Information Centre

The National Institute of Aging (NIA)

The Supreme Court of Japan

The University of Aberdeen

The University of Cologne

The University of Pittsburgh

Trinity College Dublin

United Nations (UN)

World Health Organisation (WHO)

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com